Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 45,042,700 | 34,124,100 | 28,541,400 | 28,318,400 | 24,539,800 |
| Cost of Goods | 8,418,300 | 7,082,200 | 6,629,800 | 7,312,800 | 5,483,300 |
| Gross Profit | 36,624,400 | 27,041,900 | 21,911,600 | 21,005,600 | 19,056,500 |
| Operating Expenses | 23,725,700 | 20,584,200 | 14,785,100 | 14,649,300 | 12,998,800 |
| Operating Income | 12,899,000 | 6,457,900 | 7,127,301 | 6,357,102 | 6,058,002 |
| Other Income | -218,600 | 96,700 | -320,901 | -201,602 | 1,171,898 |
| Pre-tax Income | 12,680,400 | 6,554,600 | 6,806,400 | 6,155,500 | 7,229,900 |
| Income Tax | 2,090,400 | 1,314,200 | 561,600 | 573,800 | 1,036,200 |
| Net Income Continuous | 10,590,000 | 5,240,400 | 6,244,800 | 5,581,700 | 6,193,700 |
| Net Income | $10,590,000 | $5,240,400 | $6,244,800 | $5,581,700 | $6,193,700 |
| EPS Basic Total Ops | 11.76 | 5.82 | 6.93 | 6.15 | 6.82 |
| EPS Basic Continuous Ops | 11.76 | 5.82 | 6.93 | 6.15 | 6.82 |
| EPS Diluted Total Ops | 11.71 | 5.80 | 6.90 | 6.12 | 6.79 |
| EPS Diluted Continuous Ops | 11.71 | 5.80 | 6.90 | 6.12 | 6.79 |
| EPS Diluted Before Non-Recurring Items | 12.99 | 6.32 | 7.94 | 8.16 | 7.93 |
| EBITDA(a) | $14,665,600 | $7,985,200 | $8,649,801 | $7,904,702 | $7,381,902 |